Objective
to assess the 10-year clinical outcomes of stenting with polymer-free sirolimus and probucol-eluting stents compared to durable zotarolimus-eluting stents
Study
multicentre randomised 2:1 trial
Population
patients with evidence of ischaemia or ischaemic symptoms excluding left main disease
Endpoints
composite death, target vessel MI, target lesion revascularisation at 10 years
Conclusion
there was no difference in the MACE rates at 10-year follow-up between treatment with SES/probucol stent (polymer-free) and ZES stent (durable polymer)
Kufner et al. J Am Coll Cardiol. 2020;76:146-58
